Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors (PRT-BC)
A Single-Arm Pilot Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors
The goal of this study is to evaluate the feasibility, acceptability, and preliminary clinical effects of an oncology-adapted Pain Reprocessing Therapy (PRT) intervention for women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). AIMSS is a common complication of aromatase inhibitor therapy for estrogen receptor-positive breast cancer and is associated with chronic pain, functional impairment, and premature discontinuation of endocrine therapy. The study will evaluate whether a six-session, manualized PRT intervention delivered remotely by trained palliative care therapists is feasible to implement and shows preliminary evidence of improving pain and physical function.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jonathan Song
- 전화번호: 734-615-1279
- 이메일: wmsong@umich.edu
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- History of ductal carcinoma in situ (DCIS) or Stage I-III estrogen receptor-positive breast cancer.
- Post-menopausal prior to starting AI or receiving luteinizing hormone-releasing hormone (LHRH) agonist therapy.
- Currently taking aromatase inhibitor therapy - anastrozole, exemestane, or letrozole - for adjuvant treatment of breast cancer or for chemoprevention.
- Current aromatase inhibitor therapy for at least 3 weeks and no more than 2 years prior to enrollment.
- Diagnosis of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), defined as new or worsening joint pain and/or myalgias since starting aromatase inhibitor therapy,
- Have had at least 3 months of recovery since the last invasive surgery
- Adequate home internet access, defined as reliable access to a private internet connection or cellular data service that supports real time two-way audiovisual telehealth visits using the University of Michigan-approved video conferencing platform on a computer tablet or smartphone. Participants must be able to complete study telehealth visits from a private location.
Exclusion Criteria:
- Evidence of active cancer or progression of disease on most recent imaging, confirmed with the treating oncologist.
- Planned invasive surgery during Day 0-60, that could interfere with study participation, pain assessment, or functional outcomes.
- Concurrent inflammatory arthropathy or autoimmune disorder.
- Patient self-report or EMR documentation of moderate to severe memory impairment or a dementia diagnosis as these would interfere with the ability to understand and remember key elements of the intervention.
- Current participation in cognitive behavioral therapy or other psychological therapy for pain, as concurrent pain-focused psychotherapy could confound interpretation of the effects of the study intervention. If they received psychotherapy in the past, they must be at least 30 days from their last session to enroll.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Treatment Arm
PRT is a form of psychotherapy that incorporates pain neuroscience education (reframing chronic pain as a predominantly safe signal arising from the brain and nervous system rather than as something that only arises from damaged tissues) with mindfulness meditation and graded exposure strategies. . For this study, PRT has been adapted for the oncology and cancer survivorship context, and includes attention to cancer-related uncertainty, fear of recurrence, medical trauma, treatment-related bodily changes, and concerns about pain as a possible signal of cancer progression. The intervention is manualized and delivered over six sessions. |
All participants will be asked only to participate in six 30-45 min intervention sessions. Participants will need to complete the sessions in the order specified. PRT will be delivered remotely by trained palliative care therapists using a HIPAA compliant secure video conferencing platform. Each session will last approximately 30-45 minutes. The intervention will be delivered in English only. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recruitment - Number
기간: 11 months of recruitment activity
|
Number of approached patients who consent to participate. |
11 months of recruitment activity
|
|
Recruitment - proportion
기간: 11 months of recruitment activity
|
Proportion of approached patients who consent to participate. |
11 months of recruitment activity
|
|
Retention - Assessments completed
기간: 180 days
|
Mean number of post intervention assessments completed per subject; |
180 days
|
|
Retention - Proportion
기간: 180 days
|
proportion of subjects completing the Day 60 and Day 180 assessments |
180 days
|
|
Intervention Uptake: PRT Sessions count
기간: 60 days
|
Mean number of PRT sessions attended per subject |
60 days
|
|
Intervention Uptake: proportions of participants
기간: 60 days
|
proportion completing at least 4 of 6 sessions and proportion completing all 6 sessions. |
60 days
|
|
Representativeness:
기간: 11 months of enrollment activity
|
The demographic and clinical characteristics of enrolled participants vs. those of potentially eligible patients identified from the University of Michigan Rogel Cancer Center source population during the recruitment period. |
11 months of enrollment activity
|
|
Intervention fidelity.
기간: 60 days of intervention
|
Intervention fidelity will be assessed through structured session checklists completed by interventionists after each visit, documenting delivery of required PRT components, session duration, and any deviations from the manual. |
60 days of intervention
|
|
Acceptability of PRT intervention
기간: after 60 days of intervention
|
Treatment Acceptability and Adherence Scale (TAAS), a 10-item scale assessing perceived acceptability and usefulness of a behavioral intervention.(Milosevic et al., 2015) Scores above the midpoint - 35 out of 70 - will denote moderate acceptability of the intervention). |
after 60 days of intervention
|
|
Participant satisfaction
기간: after 60 days of intervention
|
The CSQ-8 yields a total score ranging from 8 to 32, with higher scores indicating greater satisfaction. |
after 60 days of intervention
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pain severity
기간: up to 180 days
|
Pain severity will be measured using a 0-10 Numeric Rating Scale (NRS) assessing average pain over the prior 7 days, with anchors of 0 ("no pain") and 10 ("worst pain imaginable") (Jensen et al., 1986). |
up to 180 days
|
|
Change in Pain impact
기간: up to 180 days
|
Pain impact will be assessed using the Pain, Enjoyment of Life, and General Activity (PEG) scale, a validated 3-item composite measure of pain severity and pain-related interference (Keller et al., 2004; Krebs et al., 2010). |
up to 180 days
|
|
Pain Interferece
기간: up to 180 days
|
Pain interference will be assessed using the PROMIS Pain Interference Short Form 6b, a 6-item measure evaluating the extent to which pain interferes with daily activities, social participation, and enjoyment of life over the past 7 days |
up to 180 days
|
|
Physical Function T-scores
기간: up to 180 days
|
Physical function will be measured using the PROMIS Physical Function 4a, a validated 4-item patient-reported measure of physical functioning. Scores will be converted to standardized T-scores, with higher scores indicating better physical function |
up to 180 days
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Maria Silveira, MD, University of Michigan
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- UMCC 2026.079
- U54AG0923230 (기타 보조금/기금 번호: National Institutes of Health)
- HUM00292989 (기타 식별자: University of Michigan Rogel Cancer Center)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Deidentified patient quantitative data and qualitative transcripts will be provided to a data repository at the University of Colorado which will gather the data on behalf of the National Institute of Aging.
IPD 공유 기간
within 12 months of last participant completing study
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .